Edition:
United States

Dae Hwa Pharm Co Ltd (067080.KQ)

067080.KQ on KOSDAQ - Korea Secs Dealers Association Quotation

20,700.00KRW
27 Apr 2017
Change (% chg)

₩-250.00 (-1.19%)
Prev Close
₩20,950.00
Open
₩21,100.00
Day's High
₩21,200.00
Day's Low
₩20,700.00
Volume
79,851
Avg. Vol
113,895
52-wk High
₩51,200.00
52-wk Low
₩18,600.00

067080.KQ

Chart for 067080.KQ

About

DAE HWA PHARM CO.,LTD. is a Korea-based company engaged in the manufacture of pharmaceuticals. The Company’s products include skeletal muscle relaxants, gastro-intestinal drugs, corticosteroids, antihistamines, cardiovascular drugs, drugs for liver diseases, vitamins, tonics, antibiotics, injections, topical drugs, anti-inflamma... (more)
No analyst recommendations are available for 067080.KQ.

Overall

Beta: 0.21
Market Cap(Mil.): ₩381,813.19
Shares Outstanding(Mil.): 18.22
Dividend: 50.00
Yield (%): 0.48

Financials

  067080.KQ Industry Sector
P/E (TTM): 99.19 29.39 30.30
EPS (TTM): 211.21 -- --
ROI: 4.78 13.71 13.24
ROE: 5.86 14.66 14.40

BRIEF-Dae Hwa Pharm to pay annual dividend as 50 won/share for FY 2016

* Says it plans to pay annual cash dividend as 50 won/share for FY 2016, to shareholders of record on Dec. 31, 2016

Feb 09 2017

BRIEF-Dae Hwa Pharm receives patent

* Says it receives patent about pharmaceutical composition for prevention or treatment of cognitive function disorder comprising spinosin

Jan 16 2017

BRIEF-Dae Hwa Pharm unit RedoxBio to raise 10.04 bln won via private placement

* Says its unit RedoxBio Co.,Ltd will issue 10.0 million shares of the company through private placement, at 1,000 won per share, to raise 10.04 billion won in proceeds for operations and investment as well as other funds

Nov 22 2016

BRIEF-Dae Hwa Pharm receives patent

* Says it receives Japan patent on Nov. 7, for pharmaceutical composition for prevention or treatment of cognitive function disorder comprising spinosin

Nov 07 2016

More From Around the Web

Earnings vs. Estimates

No consensus analysis data available.